Table 3. Results of pairwise and network meta-analyses for the rate of adverse events.
| Dex 30 | 1.15(0.83, 1.61);p-value: 0.4 | NA | NA | NA | NA | NA | NA | 1.15(0.82, 1.6);p-value: 0.41 | NA | NA | NA |
| 1.15(0.65,2.04);p-value: 0.63 | Dex 60 | NA | NA | NA | NA | NA | NA | 0.99(0.71, 1.39);p-value: 0.98 | NA | NA | NA |
| 1.11(0.53,2.33);p-value: 0.78 | 0.97(0.46,2.02);p-value: 0.94 | Eso 20 | 0.87(0.61, 1.24);p-value: 45 | NA | NA | NA | NA | 1(0.7, 1.43);p-value:0.99 | NA | NA | NA |
| 1.00(0.48,2.08);p-value: 1 | 0.86(0.41,1.81);p-value: 0.69 | 0.89(0.56,1.42);p-value: 0.62 | Eso 40 | NA | NA | NA | NA | 1.14(0.8, 1.64);p-value: 0.46 | NA | NA | NA |
| 1.02(0.35,2.97);p-value: 0.97 | 0.88(0.30,2.58);p-value: 0.82 | 0.92(0.33,2.54);p-value: 0.87 | 1.02(0.37,2.84);p-value: 0.97 | Lan 15 | 0.79(0.5, 1.24);p-value: 0.31 | NA | NA | 1.12(0.52, 2.44);p-value: 0.77 | NA | NA | NA |
| 0.81(0.28,2.34);p-value: 0.7 | 0.70(0.24,2.03);p-value: 0.51 | 0.73(0.26,1.99);p-value: 0.55 | 0.81(0.30,2.23);p-value: 0.68 | 0.79(0.41,1.51);p-value: 0.48 | Lan 30 | NA | NA | 1.42(0.66, 3.05);p-value: 0.37 | NA | NA | NA |
| 1.23(0.58,2.58);p-value: 0.59 | 1.06(0.51,2.24);p-value: 0.88 | 1.10(0.56,2.16);p-value: 0.78 | 1.23(0.63,2.41);p-value: 0.54 | 1.20(0.43,3.34);p-value: 0.73 | 1.52(0.55,4.19);p-value: 0.42 | Ome 10 | 1.23(0.57, 2.65);p-value: 0.6 | 0.88(0.45, 1.69);p-value: 0.69 | NA | NA | NA |
| 1.37(0.64,2.92);p-value: 0.42 | 1.18(0.55,2.54);p-value: 0.67 | 1.23(0.61,2.46);p-value: 0.56 | 1.37(0.69,2.74);p-value: 0.37 | 1.34(0.48,3.77);p-value: 0.58 | 1.69(0.60,4.72);p-value: 0.32 | 1.11(0.69,1.80);p-value: 0.67 | Ome 20 | 0.82(0.48, 1.4);p-value: 0.46 | NA | NA | NA |
| 1.15(0.65,2.03);p-value: 0.63 | 0.99(0.56,1.76);p-value: 0.97 | 1.03(0.65,1.64);p-value: 0.9 | 1.15(0.72,1.84);p-value: 0.56 | 1.12(0.45,2.78);p-value: 0.81 | 1.42(0.58,3.48);p-value: 0.44 | 0.94(0.58,1.51);p-value: 0.8 | 0.84(0.51,1.39);p-value: 0.49 | Pla | 0.79(0.55, 1.55);p-value: 0.22 | 0.86(0.39, 1.92);p-value: 0.72 | 1.03(0.56, 1.9);p-value: 0.91 |
| 0.92(0.45,1.88);p-value: 0.82 | 0.80(0.39,1.63);p-value: 0.54 | 0.83(0.43,1.57);p-value: 0.58 | 0.92(0.49,1.75);p-value: 0.8 | 0.90(0.33,2.46);p-value: 0.84 | 1.14(0.42,3.08);p-value: 0.8 | 0.75(0.39,1.42);p-value: 0.39 | 0.67(0.35,1.29);p-value: 0.23 | 0.80(0.52,1.24);p-value: 0.31 | Rab 10 | 0.82(0.37, 1.85);p-value: 0.64 | 1.1(0.61, 1.99);p-value: 0.75 |
| 0.85(0.32,2.24);p-value: 0.74 | 0.73(0.28,1.94);p-value: 0.52 | 0.76(0.30,1.90);p-value: 0.56 | 0.85(0.34,2.13);p-value: 0.73 | 0.83(0.25,2.75);p-value: 0.76 | 1.05(0.32,3.45);p-value: 0.94 | 0.69(0.27,1.74);p-value: 0.44 | 0.62(0.24,1.59);p-value: 0.32 | 0.74(0.33,1.62);p-value: 0.46 | 0.92(0.41,2.07);p-value: 0.84 | Rab 20 | NA |
| 1.09(0.44,2.69);p-value: 0.85 | 0.95(0.38,2.33);p-value: 0.91 | 0.98(0.42,2.27);p-value: 0.96 | 1.10(0.47,2.54);p-value: 0.83 | 1.07(0.34,3.35);p-value: 0.91 | 1.35(0.43,4.20);p-value: 0.61 | 0.89(0.38,2.06);p-value: 0.79 | 0.80(0.34,1.88);p-value: 0.61 | 0.95(0.48,1.91);p-value: 0.88 | 1.19(0.60,2.37);p-value: 0.62 | 1.29(0.47,3.55);p-value: 0.62 | Rab 5 |
Results of pairwise meta-analyses were listed in right upper triangles and results of network meta-analyses were listed in left lower triangles. Rab 5: Rabeprazole 5 mg; Rab 10: Rabeprazole 10 mg; Rab 20: Rabeprazole 20 mg; Pla: Placebo; Dex 30: Dexlansoprazole 30 mg; Dex 60: Dexlansoprazole 60 mg; Ome 10: Omeprazole 10 mg; Ome 20: Omeprazole 20 mg; Lan 15: Lansoprazole 15 mg; Lan 30: Lansoprazole 30 mg; Eso 20: Esomeprazole 20 mg; Eso 40: Esomeprazole 40 mg.